CD86 and cancer: Given that CD86, as a co‐stimulatory molecule, interacts with CD28 for T‐cell activation and survival,[37] the loss of CD86 expression in TAM Macro‐2 may result from a cancer cell‐induced program in the PCa microenvironment.